Substance use in persons with schizophrenia: Incidence, baseline correlates, and effects on outcome

Antipsychotic Trials in Schizophrenia: The CATIE Project

Volumn , Issue , 2010, Pages 189-206

  Reimherr, Fred ^a   Swartz, Marvin S ^b   Olsen, John L ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054063840     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511712265.012     Document Type: Chapter

References (29)

1. Blanchard JJ, Brown SA, Horan WP and Sherwood AR. Substance use disorders in schizophrenia: Review, integration, and a proposed model. Clinical Psychology Review 2000;20:207–34.
2. Cantor-Graae E, Nordstrom LG and McNeil TF. Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophrenia Research 2001;48:69–82.
3. Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophrenia Research 1999;35: S93–S100.
4. Goswami S, Mattoo SJ, Basu D and Singh G. Substance-abusing schizophrenics: Do they self-medicate? The American Journal on Addictions 2004;13:139–50.
5. Kavanagh DJ, McGrath J, Saunders JB, Dore G and Clark D. Substance misuse in patients with schizophrenia: Epidemiology and management. Drugs 2002;62:743–55.
6. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J and Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 1997;54:313–21.
7. McCreadie RG. Use of drugs, alcohol and tobacco by people with schizophrenia: Case-control study. British Journal of Psychiatry 2002;181:321–5.
8. Mueser KT, Drake RE and Wallace MA. Dual diagnosis: A review of etiological theories. Addictive Behaviors 1998; 23:717–34.
9. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association 1990;264:2511–8.
10. Salyers MP and Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophrenia Research 2001;48:109–23.
11. Haywood TW, Kravita HM, Grossman LS, Cavanaugh JL Jr, Davis JM and Lewis DA. Predicting the “revolving door” phenomenon among patient with schizophrenic, schizoaffective, and affective disorders. American Journal of Psychiatry 1995;151:856–61.
12. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner HR and Burns BJ. Violence and severe mental illness: The effects of substance abuse and nonadherence to medication. American Journal of Psychiatry 1998;155:226–31.
13. Swofford CD, Kasckow JW, Scheller-Gilkey G and Inderbitzin LB. Substance use: A powerful predictor of relapse in schizophrenia. Schizophrenia Research 1996;20:145–51.
14. Swanson J, Estroff S, Swartz M, et al. Violence and severe mental disorder in clinical and community populations: The effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry 1997;60:1–22.
15. Goodman LA, Salyers MP, Mueser KT, et al. Recent victimization in women and men with severe mental illness: Prevalence and correlates. Journal of Traumatic Stress 2001;14:615–32.
16. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, Hepatitis B and Hepatitis C in people with severe mental illness. American Journal of Public Health 2001;91:31–7.
17. Abram K and Teplin L. Co-occurring disorders among mentally ill jail detainees: Implications for public policy. The American Psychologist 1991;46:1036–44.
18. Swartz MS, Swanson JW and Hannon MJ. Detection of illicit substance use in persons with schizophrenia. Psychiatric Services 2003;54:891–5.
19. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
20. Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease 2006;194:164–72.
21. Swartz MS, Wagner HR, Swanson JW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services 2006; 57:1110–6.
22. Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications inpatientswhouse or avoidillicit substances: Results from the CATIE study. Schizophrenia Research 2008;100:39–52.
23. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for Axes I and II DSM-IV Disorders-Patient Edition (SCID-I/P). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
24. Drake R, Osher FC, Noordsy DL, Hurlbut SC, Teague GB and Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990;16:57–67.
25. Addington D, Addington J and Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research 1990;3:247–51.
26. Kay SR, Fiszbein A and Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
27. Heinrichs DW, Hanlon TE and Carpenter WT Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–98.
28. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Offie of Applied Studies. National Survey on Drug Use and Health. Washington, DC: HHS; 2006.
29. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.